Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe

Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”

The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic crisis.”

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

Cardium Therapeutics (NYSE MKT: CXM) today announced that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product was selected as one of the top ten podiatry innovations in 2012 by the publication Podiatry Today. The Company also announced that it will be introducing Excellagen at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012 in Washington, DC.